Oncodesign Precision Medicine Announces a 6 Million Euros Bank Financing from Caisse d’Épargne Bourgogne Franche Comté, Crédit Agricole de Champagne Bourgogne and Société Générale - Seite 2

Karine Lignel, COO of Oncodesign Precision Medicine, added: “Over time, we have developed a relationship of trust with our shareholders, who supported us during OPM's last capital increase, and with regional banking institutions, which have recognized the value of our projects, even though this is not a traditional financing for them. This proves, if proof were needed, that trust is developed over time and is strengthened by successful projects such as last year's sale of Oncodesign Services and the creation of OPM. Our cash visibility has therefore improved, and we are working to complete this bank financing through government funding.”

David Sarret, Head of Healthcare Experts Division of Caisse d'Epargne Bourgogne Franche-Comté, concluded: “As a funder of the healthcare sector and innovative companies, the Caisse d'Epargne Bourgogne Franche-Comté is proud to contribute to the financing of research & development activities of Dijon-based biotech Oncodesign Precision Medicine by playing the role of arranger and agent during the transaction. This personalized financing, structured in close collaboration with Oncodesign Precision Medicine's management team, is entirely in phase with our commitment to support healthcare actors in their value-creation projects over the long term.”

About Oncodesign Precision Medicine (OPM)

Oncodesign Precision Medicine (OPM), the result of the transfer of Oncodesign's Biotech and AI activities, is a biopharmaceutical company specializing in precision medicine to treat resistant and metastatic cancers.

OPM's innovative technologies are (i) OncoSNIPER for the selection of therapeutic targets using artificial intelligence; (ii) Nanocyclix for the design and selection of macrocyclic small molecule kinase inhibitors and (iii) Promethe for the design and selection of radiolabeled biological molecules for systemic radiotherapy.

From these technologies, OPM has built a portfolio of therapeutic products. A first drug candidate based on the Nanocyclix technology entered the clinical phase in 2022, in partnership with SERVIER (which exercised its option for an exclusive worldwide license on the program) to treat Parkinson's disease. OPM-101 is OPM's second candidate to enter the clinic, in the treatment of chronic immuno-inflammatory diseases. Finally, OPM is also collaborating with Servier to discover new therapeutic targets for the treatment of pancreatic adenocarcinoma based on its OncoSNIPER technology. In addition, OPM is seeking a partner for Florepizol, a radiotracer specific for the mutated EGFR target, which has successfully completed Phase I. Finally, OPM has a significant portfolio of early-stage projects with Nanocyclix and Promethe in oncology. With this portfolio of molecules and diversified therapeutic targets, OPM's mission is to discover effective therapies to treat resistant and advanced cancers. Based in Dijon, at the heart of the university and hospital cluster, OPM has 25 employees.

More info at: oncodesign.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20231005370180/en/

The ONCODESIGN PRECISION MEDICINE Stock at the time of publication of the news with a raise of +5,08 % to 1,965EUR on Frankfurt stock exchange (05. Oktober 2023, 09:15 Uhr).